A Single Institution Experience of Bortezomib for GVHD in a Pediatric
HSCT Population
Abstract
Acute graft versus host disease (aGvHD) remains one of the most serious
complications, occurring in about 30-70%, of allogeneic hematopoietic
stem cell transplantation (HSCT) recipients. While about 40-60% of
these recipients will respond to steroids as first line, there is no
consensus on second line agents. The management of steroid-refractory
(SR) and steroid dependent (SD) GVHD after HSCT continues to be
challenging. In the absence of clinical trials, treatment in most cases
is based on individual physician or center experience. Herein, we
present our institutional experience with the use of bortezomib, a
first-generation reversible proteasome inhibitor, in SD aGvHD.